US Patent 7858740 Exendin agonist compounds
Patent 7858740 was granted and assigned to Amylin Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+232 characters)
Article
Patent abstract
Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would be benefited by lower plasma glucose and delaying and/or slowing gastric emptying.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07858740 Exendin agonist compounds US Patent 7858740 Exendin agonist compounds
Infobox
Patent Number
0785874000
Patent Number
785874000
Edits on 29 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078587400
Date of Patent
December 28, 2010
0Patent Application Number
115117380
Date Filed
August 28, 2006
0Official Website
Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078587400
Date of Patent
December 28, 2010
0Patent Application Number
115117380
Date Filed
August 28, 2006
0Official Website
Patent Primary Examiner
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07858740 Exendin agonist compounds
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07858740
Date of patent
December 28, 2010
Patent application number
11511738
Date Filed
August 28, 2006
Patent primary examiner
Find more entities like US Patent 7858740 Exendin agonist compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
